RE:RE:RE:RE:RE:Theralase Is still Flying Under the RadarYes, when Dr. Kamat spoke about "new kids on the block", he was referring to bladder cancer drugs which may well get FDA approval in the next few months and thereupon become an option in treating bladder cancer patients. Theralase will not even be applying for breakthrough designation and possibly AA until the end of the year. So a mention of TLD1433 here would have been premature.
ScienceFirst wrote: Eoganacht ... Indeed, Dr. Kamat's initial mandate was not to promote our drug. But to advise Theralase in the design of the Ph. 2.
Contrary to the other drugs mentioned (N-803 with BCG, ...), these drugs have completed their trials, which is not the case of TLT yet. But for sure, if we obtain Breakthrough designation, this will be much easier for Dr. Kamat to put things into perspectives, talk about it in a non-partisan way and more in a scientifical way.